Item 8.01 Other Events.
Update on Global Access to Sotrovimab for COVID-19 Patients
Vir Biotechnology, Inc. (the "Company") today announced significant progress
increasing global patient access to sotrovimab, an investigational monoclonal
antibody treatment for COVID-19 developed in partnership with GlaxoSmithKline.
To date, binding agreements have been received for the sale of more than 420,000
doses of sotrovimab worldwide, including a portion of those procured by the U.S.
government. In addition, more than 220,000 doses have been reserved through
other agreements. The companies continue discussions with governments around the
world for additional agreements that can support the ongoing pandemic response.
Forward-Looking Statements
This Current Report on Form 8-K contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Words such as
"may," "will," "plan," "potential," "aim," "promising" and similar expressions
(as well as other words or expressions referencing future events, conditions or
circumstances) are intended to identify forward-looking statements. These
forward-looking statements are based on the Company's expectations and
assumptions as of the date of this Current Report on Form 8-K. Forward-looking
statements contained in this Current Report on Form 8-K include a statement by
the Company's regarding discussions with governments around the world for the
purchase of sotrovimab in the treatment of COVID-19. Other factors that may
cause actual results to differ from those expressed or implied in the
forward-looking statements in this press release are discussed in the Company's
filings with the U.S. Securities and Exchange Commission, including the section
titled "Risk Factors" contained therein. Except as required by law, the Company
assumes no obligation to update any forward-looking statements contained herein
to reflect any change in expectations, even as new information becomes
available.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses